Search
Eslicarbazepine acetate
go.drugbank.com/drugs/DB09119ApprovedInvestigationalEslicarbazepine's mechanism of action is not well understood, but it is known that it does exert anticonvulsant activity by inhibiting repeated neuronal firing and stabilizing the inactivated state of … Eslicarbazepine acetate (ESL) is an anticonvulsant medication approved for use in Europe, the United States and Canada as an adjunctive therapy for partial-onset seizures that are not adequately controlled
Amiloxate
go.drugbank.com/drugs/DB11207ApprovedAmiloxate is an EMA-approved chemical UV-filter found in over-the-counter sunscreen products at concentrations up to 10%m [F35]. … It is often referred to as isoamyl 4-methoxycinnamate or isoamyl p-methoxycinnamate. Amiloxate is a cinnamic acid derivative with an anti-inflammatory activity [A32916].
Mixtures: Dpc Pink Aura Cushion No.21, Dpc Pink Aura Cushion No.23Varenicline
go.drugbank.com/drugs/DB01273ApprovedInvestigationalVarenicline is a prescription medication used to treat smoking addiction. This medication is the first approved nicotinic receptor partial agonist. … In addition it acts on alpha3/beta4 and weakly on alpha3beta2 and alpha6-containing receptors. A full agonism was displayed on alpha7-receptors. On March 9, 2015, the U.S.
Cyclobenzaprine
go.drugbank.com/drugs/DB00924ApprovedInvestigational[A184982] It was initially studied for use as antidepressant given its structural similarity to tricyclic antidepressants - it differs from [Amitriptyline] by only a single double bond. … [A185039,A184982] Since its approval, it has remained relatively popular as an adjunctive, short-term treatment for acute skeletal muscle spasms secondary to musculoskeletal injury.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeSynonyms: N,N-dimethyl-5H-dibenzo(a,d)cycloheptene-Δ5,γ-propylamineSynthetic Conjugated Estrogens, A
go.drugbank.com/drugs/DB09317ApprovedEstrogens act by binding to estrogen receptors on a wide variety of tissues in the body and modulating the pituitary secretion of the gonadotropins, luteinizing hormone (LH) and follicle stimulating hormone … There is currently no generic form of CEEs available as a detailed analytical characterization of the active ingredients or of their estrogenic activity is not available at this time.
Cantharidin
go.drugbank.com/drugs/DB12328ApprovedInvestigational[A32892] Nevertheless, it gained its first FDA approval on Jul 21, 2023, under the brand name YCANTH™ by Verrica Pharmaceuticals for the treatment of molluscum contagiosum in adult and pediatric patients … [A32891, A32892] Topical cantharidin products do not necessarily demonstrate any particular better effectiveness at treating topical skin conditions like warts than other commonly available vesicant
Ticlopidine
go.drugbank.com/drugs/DB00208ApprovedTiclopidine is marketed under the brand name Ticlid and is indicated for patients who cannot take aspirin or in whom aspirin has not worked to prevent a thrombotic stroke. … It is a prodrug that is metabolised to an active form, which blocks the ADP receptor that is involved in GPIIb/IIIa receptor activation leading to platelet aggregation.
Amphotericin B
go.drugbank.com/drugs/DB00681ApprovedInvestigationalHistoplasma capsulatum, Coccidioides immitis, Candida species, Blastomyces dermatitidis, Rhodotorula, Cryptococcus neoformans, Sporothrix schenckii, Mucor mucedo, and Aspergillus fumigatus are all inhibited by … While Candida albicans is generally quite susceptible to amphotericin B, non-albicans species may be less susceptible. Pseudallescheria boydii and Fusarium sp. are often resistant to amphotericin B.
Darolutamide
go.drugbank.com/drugs/DB12941ApprovedInvestigational[A189054,A189063] Darolutamide was developed by Bayer HealthCare Pharmaceuticals Inc. and approved by the FDA on July 30th, 2019.[L10887] … Darolutamide is a nonsteroidal androgen receptor antagonist for the treatment of castrate-resistant, non-metastatic prostate cancer (nmCRPC).
Categories: Antiandrogens, non-steroidalBebtelovimab
go.drugbank.com/drugs/DB16755ApprovedWithdrawn[L40328] Bebtelovimab was issued an emergency use authorization (EUA) by the FDA on February 11, 2022, for the treatment of mild-to-moderate COVID-19 in select patients. … in the treatment of COVID-19 caused by the Omicron variant.